Cell and Gene Therapy Companies Market Position Advancements, Value Creation, Cross-border Expansion, Patent Expansions, Financial Performance Evaluation

Cell and Gene Therapy Key Players and their Developments

The global cell and gene therapy market size is calculated at USD 21.82 billion in 2024 and is expected to be worth USD 187.44 billion by 2034, expanding at a CAGR of 24% from 2024 to 2034.

Competitive Landscape

The cell and gene therapy market has experienced remarkable growth and progress in recent years, holding immense potential for transforming healthcare with personalized and targeted therapies. Several key players dominate the competitive landscape in this field. To gain a larger share of the market, players are using strategies like investments, alliances, acquisitions, and mergers.

Some of the major market companies include Alnylam Pharmaceuticals Inc., Amgen Inc., Biogen Inc., CORESTEM Inc., Dendreon Pharmaceuticals LLC., Helixmith Co. Ltd., JCR Pharmaceuticals Co. Ltd., Kolon TissueGene Inc., Novartis AG, and Pfizer Inc.

Recent Developments in the Cell and Gene Therapy Market

• In November 2024, iotaSciences announced the launch of its newly developed Single-Cell Cloning Platform XT, a fluid shaping technology, at the Cell 2024 in London. The instrument was developed to facilitate stem cell handling and gene editing.
• In July 2024, Miltenyi Biotec announced a collaboration with the Translational Health Science and Technology Institute (THSTI) to address the growing demand for innovative treatments for cancer and sickle cell disease by developing cell and gene therapies.
• In October 2024, researchers from the University of California developed a novel technology that can easily create a gateway into the nucleus. The technique could open new possibilities in gene therapy, drug delivery, and other forms of personalized medicine.

Cell and Gene Therapy Market: Pharmaceutical Shipping Data Overview